Posted On: 10/06/2016 7:39:34 PM
Post# of 30066
.jpg)
here's the text and link for what Red just reported https://www.sec.gov/Archives/edgar/data/14248...rantus.htm
Item 1.02 Termination of a Material Definitive Agreement
On September 30, 2016, Lonza Walkersville, Inc. (“Lonza”) informed Amarantus Bioscience Holdings, Inc. (the “Company”) that the Manufacturing Services Agreement dated as of July 14, 2015 between Lonza and the Company (the “MSA”) with respect to the manufacture of the Company’s ESS product, had been terminated by Lonza pursuant to the terms of the MSA due to lack of payment. The Company is seeking to work with Lonza to enter into a new MSA to provide for the initiation of its Phase 2 trial with the US Army, subject to funding by the Company.
Item 8.01 Other Events
On August 26th, 2016, Lonza informed the Company that it had achieved current Good Manufacturing Practices (cGMP)-readiness for the Company’s Engineered Skin Substitute Program.
In addition, the Company extended the exclusivity period of its non-binding Letter of Intent (the "LOI”) with a commercial-stage wound-care company to form a joint venture (the "JV"
for the further development of the ESS program. The exclusivity period of the LOI, has been extended for an additional 60 days to October 29, 2016.
Item 1.02 Termination of a Material Definitive Agreement
On September 30, 2016, Lonza Walkersville, Inc. (“Lonza”) informed Amarantus Bioscience Holdings, Inc. (the “Company”) that the Manufacturing Services Agreement dated as of July 14, 2015 between Lonza and the Company (the “MSA”) with respect to the manufacture of the Company’s ESS product, had been terminated by Lonza pursuant to the terms of the MSA due to lack of payment. The Company is seeking to work with Lonza to enter into a new MSA to provide for the initiation of its Phase 2 trial with the US Army, subject to funding by the Company.
Item 8.01 Other Events
On August 26th, 2016, Lonza informed the Company that it had achieved current Good Manufacturing Practices (cGMP)-readiness for the Company’s Engineered Skin Substitute Program.
In addition, the Company extended the exclusivity period of its non-binding Letter of Intent (the "LOI”) with a commercial-stage wound-care company to form a joint venture (the "JV"
for the further development of the ESS program. The exclusivity period of the LOI, has been extended for an additional 60 days to October 29, 2016.
(3)
(0)
